Full-Time

Medical Director

Invivyd

Invivyd

51-200 employees

Develops monoclonal antibodies for viral protection

Compensation Overview

$184k - $245k/yr

+ Annual Bonus + Equity

New Haven, CT, USA

In Person

Category
Biology & Biotech (2)
,
Required Skills
SAP Products
Pharmacology
Google Cloud Platform
Requirements
  • MD required
  • 7+ years of experience in clinical research or drug development from the pharmaceutical/biotechnology industry, preferably spanning clinical activities in phases I through IV
  • Medical monitoring experience required
  • Hands-on participation in successful regulatory approvals is required
  • Strong critical thinking and problem-solving skills to plan, organize, and manage resources for successful completion of projects
  • Ability to motivate, influence and collaborate with others across all levels of the organization
  • Ability to engage internal and external experts in constructive scientific dialogue around study design, conduct and data interpretation
  • Broad working knowledge of FDA requirements, industry compliance, clinical trial design and strategies
  • Experience in interacting with the FDA and/or global regulatory agencies
  • Strong general knowledge of Good Clinical Practice, Good Pharmacovigilance Practice, International Council for Harmonisation guidelines and regulatory requirements that apply to clinical drug development
  • Able to conceive and execute innovative approaches to clinical development
  • Excellent written, communication and interpersonal skills and proven success working in a multi-functional team-based environment
  • Strong project planning, negotiation, and presentation skills as well as an ability to contribute creative yet practical solutions to problems
  • Able to prioritize and parallel process multiple work streams, comfortable shifting gears and remaining flexible, as well as making definitive decisions
  • In-depth understanding of the scientific method and ability to apply this information to business needs based on medical and scientific rationale
  • Ability to travel domestically and internationally
  • Ability to travel to New Haven, CT
Responsibilities
  • In collaboration with other departments (Biometrics, Clinical Operations, Regulatory Affairs and Medical Affairs) lead the conception, study design, study protocols, medical monitoring and medical interpretation of Invivyd’s clinical trials
  • Provide clinical leadership and medical strategic input for deliverables in the assigned project/program. Deliverables will include sections of individual protocols consistent with the clinical development plan (CDP), data review, program specific standards, clinical components of regulatory documents/registration dossiers, and publications (e.g., investigator brochures, briefing books, safety updates, submission dossiers, and responses to health authorities)
  • Lead the timely drafting of clinical responses to questions from regulatory authorities
  • Provide medical review and approval of promotional and medical materials in compliance with corporate standards and government/industry regulations
  • Oversee the development and management of clinical protocols and amendments, investigator brochures, and clinical study reports
  • Develop and maintain close professional relationships with key thought leaders and healthcare practitioners within the medical and scientific community
  • Provide impactful medical expertise to clinical, commercial, market access and regulatory partners
  • Oversee the evaluation of safety, pharmacology, and efficacy data from ongoing and completed studies
  • Oversee manuscripts, abstracts and presentations for scientific meetings and advisory boards
  • Conduct literature reviews and prepare summaries to support clinical development programs
  • Serve as a medical resource for design and interpretation of clinical and preclinical programs to support existing and new development candidates
  • Contribute to clinical trial documents including protocol, ICF, study plans and SAP
  • May serve as a medical monitor for one or more studies
Desired Qualifications
  • Experience with monoclonal antibodies or vaccines strongly preferred

Invivyd develops antibody-based therapies to protect immunocompromised people from viral threats. It discovers and optimizes monoclonal antibodies using viral surveillance, predictive modeling, and antibody engineering, aiming to prevent infections such as COVID-19 in high-risk groups. Its lead candidate VYD222 targets prevention of symptomatic COVID-19 in transplant recipients and people with blood cancers. The company plans to commercialize these antibodies through development, approvals, and partnerships, while pursuing government funding to support research for vulnerable populations.

Company Size

51-200

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

2020

Simplify Jobs

Simplify's Take

What believers are saying

  • DECLARATION Phase 3 trial fully enrolled with mid-2026 data readout for VYD2311 launch.
  • PEMGARDA revenue grew 31% sequentially in Q4 2025, validating antibody prophylaxis market demand.
  • Pipeline expansion into measles, RSV, and long COVID addresses multiple high-need viral indications.

What critics are saying

  • Low COVID community attack rates force 30% trial expansion, risking 6-9 month data delay.
  • Stock price below $1 triggers Nasdaq delisting risk, halting institutional investment and capital access.
  • Competing extended half-life COVID antibodies from AstraZeneca and Regeneron capture immunocompromised market share.

What makes Invivyd unique

  • Proprietary platform combines viral surveillance, predictive modeling, and antibody engineering for evolved immunity.
  • Targets immunocompromised populations underserved by traditional vaccines with monoclonal antibody prophylaxis.
  • FDA Fast Track designation for VYD2311 accelerates COVID-19 prevention development versus competitors.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Professional Development Budget

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-5%

2 year growth

-1%
Yahoo Finance
Mar 5th, 2026
Invivyd eyes mid-2026 data for COVID antibody VYD2311 as PEMGARDA revenue jumps 31%

Invivyd reported Q4 2025 earnings, highlighting strategic progress in monoclonal antibody prophylaxis as an alternative to COVID-19 vaccine boosting. The company's Declaration study for VYD2311 reached target enrolment of approximately 1,770 subjects, with mid-year 2026 remaining the target for pivotal data. PEMGARDA revenue grew 31% sequentially, supporting infrastructure development ahead of a potential VYD2311 launch. Management expects to decide on expanding the trial by roughly 30% in April to ensure statistical power if community attack rates fluctuate. The company reported cash of $226.7 million, providing runway through the mid-2026 data readout. Invivyd is expanding into long COVID and post-vaccine syndrome, whilst developing RSV and measles programmes with a paediatric-first approach. Management cited COVID-19 community attack rates as the primary external risk factor.

Yahoo Finance
Mar 5th, 2026
Invivyd appoints Harvard epidemiologist Michael Mina as chief medical officer

Invivyd has appointed Michael Mina, M.D., Ph.D., as Chief Medical Officer. Dr Mina is a former assistant professor of epidemiology, immunology and infectious disease at Harvard T.H. Chan School of Public Health and pathology at Harvard Medical School and Brigham and Women's Hospital. Dr Mina gained prominence during the COVID pandemic, advising governments on testing policies and leading the US government's Home Test-to-Treat Programme. His research includes discovering measles-induced "immune amnesia" and investigating antibody responses to vaccines and pathogens. He has published over 100 scientific papers with more than 10,000 citations. The appointment comes as Invivyd works to expand its pipeline of monoclonal antibodies for infectious disease prevention, including COVID, RSV and measles.

Yahoo Finance
Mar 5th, 2026
Invivyd reports $17.2M Q4 revenue for PEMGARDA, raises $200M to fund VYD2311 COVID trial

Invivyd reported fourth quarter 2025 net product revenue of $17.2 million for PEMGARDA (pemivibart), representing 25% year-over-year growth and 31% quarter-over-quarter growth. Full-year revenue more than doubled whilst operating expenses were reduced by nearly half. The company ended 2025 with $226.7 million in cash after raising over $200 million in financing transactions during the second half of the year. Invivyd has initiated the DECLARATION Phase 3 pivotal trial of VYD2311, a vaccine-alternative antibody to prevent COVID, with top-line data expected mid-2026. The FDA granted Fast Track designation for VYD2311 in December 2025. The trial has achieved full enrolment and an independent data monitoring committee has recommended allowing pregnant and breastfeeding women to participate. A potential trial re-sizing decision could occur in April.

TipRanks
Nov 17th, 2025
Invivyd Announces Common Stock Offering

Invivyd announced an underwritten public offering of its common stock, with all shares offered by the company. The proceeds will be used for commercial preparedness for VYD2311, R&D for pipeline programs like respiratory syncytial virus and measles, advancement of the SPEAR Study Group on monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome, and general corporate purposes. Cantor is the sole book-running manager for the offering.

Stock Titan
Aug 22nd, 2025
Invivyd Closes $57.5M Public Offering

Invivyd has announced the successful closing of a public offering, raising $57.5 million. The underwriter also fully exercised their option to purchase additional shares.